Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BioLase Technology, Inc. (BLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Karl Drobnic who wrote (390)	7/19/1998 9:47:00 PM
From: GemSeeker	Respond to of 706

Interesting post from Yahoo BLTI thread: >>From: lasertrix Date: Jul 18 1998 9:24AM EDT I view the FDA clearance as key. The ablative resurfacing market was worth several hundred million dollars shared by 15-20 laser companies making CO2 and then erbium systems. The latter gained popularity because they reduced post-op morbidity but they are definitely less effective at increasing skin tone. The Skin Toner is the first and only non-ablative laser available now for increasing skin tone with NO post-op morbidity. The point is that this is a unique opportunity for us in Biolase, we may never need to share this market if we gain broad patent protection. Moreover, unlike the ablative resurfacing lasers that use free-beam delivery systems, the Skin Toner uses a mandatory single-use, disposable contact delivery system which means we get significant trailing income off of each laser sale. Finally, look for enormous growth in the number of candidates for this non-invasive technology: if 350,000 resurfacing procedures were done in the USA last year, I'll bet the number of Skin Toner procedures will easily top 1M/year. Remember, this is done at an earlier stage, can be repeated as needed, and its the only system for stretch marks. With three major product launches this year, Biolase is a bargain. <<